Denali Therapeutics Inc. (NASDAQ: DNLI) Highlighted for Surprising Price Action

June 17, 2026 10:17:43

Denali Therapeutics Inc. (NASDAQ: DNLI) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 7.39% on the day to $23.55.

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials.

So far today, approximately 462.95k shares of Denali Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 1.86M shares.

Denali Therapeutics Inc. share prices have moved between a 52-week high of $23.77 and a 52-week low of $12.58. The stock has moved 4.33% over the past week.

To learn more, visit Denali Therapeutics Inc.

Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]